What is the efficacy and safety of thrombolytic therapy for peripheral arterial disease (PAD)?

Updated: Aug 04, 2021
  • Author: Wanda L Rivera-Bou, MD, FAAEM, FACEP; Chief Editor: Erik D Schraga, MD  more...
  • Print


Streptokinase was once the most widely used agent but has since been supplanted by urokinase and alteplase; prourokinase (not currently available), reteplase, and tenecteplase have been studied as well. Reteplase and tenecteplase are as safe and efficacious as tissue plasminogen activator (tPA). [64] The optimal dosages and concentrations of reteplase, alteplase, and tenecteplase are still under investigation. Alfimeprase is also under study, but more clinical studies are needed to show acceptable efficacy. [65]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!